Forbes February 19, 2025
In this week’s edition of InnovationRx, we look at a new biotech fund spearheaded by Recursion, a shift in bird flu strategy from the Trump Administration, a new vaccine approval from the FDA, Nvidia’s latest AI model for life sciences and more.
The Trump Administration policies of spending freezes and grant cuts have thrown the biotech industry into disarray. Although federal judges have placed a hold on any spending freezes, uncertainty plus persistent inflation makes it a hard environment for early-stage biotech startups to get the funds they need to keep going.
In response to these policy shifts, Recursion announced today that its biotech accelerator Altitude Lab...
Today's Sponsors
Today's Sponsor